John K. Bakewell - 15 Nov 2025 Form 4/A - Amendment Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Reporting relationship: Director
Issuer ticker: XTNT
Reported as of: 15 Nov 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 18 Nov 2025, 17:53:42 UTC
Original report date: 15 Nov 2025
Prior SEC filing: 21 May 2025
Next SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Culbert, attorney-in-fact

Key filing fact

John K. Bakewell filed Form 4/A - Amendment for Xtant Medical Holdings, Inc. (XTNT) on 18 Nov 2025.

Key facts

This page summarizes John K. Bakewell's Form 4/A - Amendment filing for Xtant Medical Holdings, Inc. (XTNT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Nov 2025, 17:53.

Change

Previous filing in this sequence was filed on 21 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001183553 Primary reporting owner

BAKEWELL JOHN K

Relationship: Director
Address: C/O XTANT MEDICAL HOLDINGS, INC., 664 CRUISER LANE, BELGRADE
Signature: /s/ Amy Culbert, attorney-in-fact
Signature date: 18 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XTNT transaction

Common Stock

Award

Transaction value: $0
Shares: +158,228
Change %: +21%
Price: $0.000000
Shares after: 914,116
Date: 15 Nov 2025
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Includes 465,570 shares issuable upon settlement of DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

Footnote F3

The purpose of this Form 4 amendment is to correct the number of shares beneficially held in column 5.